

INTRABIOTICS PHARMACEUTICALS INC /DE  
Form SC 13G/A  
February 14, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13G  
(RULE 13D-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13D-1(B), (C) AND (D) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13D-2(B)  
(AMENDMENT NO. 1)\*

Intrabiotics Pharmaceuticals, Inc.  
(Name of Issuer)

Common Stock, \$0.001 par value  
(Title of Class of Securities)

46116T100  
(CUSIP Number)

December 31, 2002  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-----  
CUSIP NO. 46116T100  
-----

13G

-----  
PAGE 2 OF 4 PAGES  
-----

- 1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
Chilton Investment Company, Inc.  
13-3667517

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ]  
(b) [X]

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION  
State of Delaware

|  |  |
|--|--|
| NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | 5. SOLE VOTING POWER<br>2,807,600      |
|  | 6. SHARED VOTING POWER<br>0            |
|  | 7. SOLE DISPOSITIVE POWER<br>2,807,600 |
|  | 8. SHARED DISPOSITIVE POWER<br>0       |

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,807,600

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See  
Instructions) [ ]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
7.4%

12. TYPE OF REPORTING PERSON (See Instructions)  
CO

CUSIP NO. 46116T100

13G

PAGE 3 OF 4 PAGES

Pursuant to Rule 13d-2(b) of Regulation 13D-G under the Securities Exchange Act of 1934, as amended, the Schedule 13G initially filed on April 1, 2002 (the "Schedule 13G") by Chilton Investment Company, Inc., with respect to the common stock \$0.001 par value (the "Common Stock") of Intrabiotics Pharmaceuticals, Inc., a Delaware corporation, is hereby amended by this Amendment No. 1 to the Schedule 13G to report a change in beneficial ownership. The Schedule 13G is hereby amended as follows:

Item 4 is hereby amended and restated in its entirety to read:

ITEM 4. OWNERSHIP.

- (a) Amount beneficially owned: 2,807,600 shares
- (b) Percent of class: 7.4%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct

Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form SC 13G/A

- the vote: 2,807,600
- (ii) Shared power to vote or to direct  
the vote: 0
- (iii) Sole power to dispose or to direct  
the disposition of: 2,807,600
- (iv) Shared power to dispose or to direct  
the disposition of: 0

-----  
CUSIP NO. 46116T100  
-----

13G

-----  
PAGE 4 OF 4 PAGES  
-----

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief,  
I certify that the information set forth in this statement is true, complete and  
correct.

Date: February 14, 2003

CHILTON INVESTMENT COMPANY, INC.

By: /s/ Norman B. Champ III

-----  
Name: Norman B. Champ III

Title: Managing Director